BRUKINSA® (zanubrutinib) is a kinase inhibitor indicated for the treatment of adult patients with:
-
Waldenström’s macroglobulinemia (WM).
-
Mantle cell lymphoma (MCL) who have received at least one prior therapy.
-
Relapsed or refractory marginal zone lymphoma (MZL) who have received at least one anti-CD20-based regimen.
The MCL and MZL indications are approved under accelerated approval based on overall response rate. Continued approval for these indications may be contingent upon verification and description of clinical benefit in confirmatory trials.
IMPORTANT SAFETY INFORMATION
Serious adverse reactions, including fatal events, have occurred with BRUKINSA, including hemorrhage, infections, cytopenias, second primary malignancies, and cardiac arrhythmias. The most common adverse reactions, including laboratory abnormalities, in ≥30% of patients included neutrophil count decreased, upper respiratory tract infection, platelet count decreased, hemorrhage, lymphocyte count decreased, rash, and musculoskeletal pain.
For the full Prescribing Information, including Important Safety Information, click here
Learn more about Brukinsa and our other areas of development at BeiGeneVirtualExperience